STOCK TITAN

PUMA BIOTECHNOLOGY INC - PBYI STOCK NEWS

Welcome to our dedicated page for PUMA BIOTECHNOLOGY news (Ticker: PBYI), a resource for investors and traders seeking the latest updates and insights on PUMA BIOTECHNOLOGY stock.

Puma Biotechnology Inc (PBYI) is a pioneering biopharmaceutical company dedicated to developing and commercializing innovative treatments for cancer. Specializing in the in-licensing of drug candidates, Puma focuses on therapies that have undergone initial clinical testing, aiming to advance these candidates for commercial use. The company's core mission is to enhance cancer care and improve patient outcomes through cutting-edge treatments.

One of Puma Biotechnology's flagship products is NERLYNX, an oral version of neratinib. This drug is specifically designed for the treatment of HER2-positive breast cancer. NERLYNX works by inhibiting the HER2 receptor, which plays a key role in the growth and spread of breast cancer cells. The effectiveness and commercial success of NERLYNX highlight Puma's commitment to providing innovative solutions in oncology.

In addition to NERLYNX, Puma is developing alisertib, a selective inhibitor of aurora kinase A. This small-molecule drug disrupts mitosis, leading to the apoptosis of rapidly proliferating tumor cells. Alisertib is targeted at various forms of cancer, making it a versatile addition to Puma's portfolio.

Puma Biotechnology's strategy involves collaboration and partnerships to bring their innovations to market. The company has a robust financial foundation, enabling it to invest in research and development while pursuing effective commercialization strategies. Puma's ongoing projects and recent achievements demonstrate its role as a significant player in the biopharmaceutical industry, consistently pushing the boundaries of cancer treatment.

For investors and stakeholders, Puma Biotechnology's focus on innovative cancer therapies and its strategic development pipeline offer promising opportunities. The company's commitment to enhancing treatment outcomes ensures it remains at the forefront of the biopharmaceutical sector.

Rhea-AI Summary
Puma Biotechnology, Inc. granted an inducement restricted stock unit award to a new non-executive employee, covering 7,500 shares of Puma common stock. The award vests over three years, with one-third of the shares vesting on the first anniversary of the award's commencement date. The award was granted under Puma's 2017 Employment Inducement Incentive Award Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
none
-
Rhea-AI Summary
Puma Biotechnology, Inc. (PBYI) CEO Alan H. Auerbach to attend TD Cowen's 44th Annual Health Care Conference in Boston. Auerbach will participate in a Breast & Lung Cancer Corporate Panel Discussion on March 6, 2024, at 9:10 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.83%
Tags
conferences
-
Rhea-AI Summary
Puma Biotechnology, Inc. (PBYI) will host a conference call to discuss its fourth quarter and full year 2023 financial results on February 29, 2024. The call will provide insights into the company's performance and future outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
conferences earnings
Rhea-AI Summary
Puma Biotechnology, Inc. (PBYI) commences ALISertib in CAncer Phase II trial for small cell lung cancer patients who have progressed on previous treatments. The trial aims to evaluate alisertib monotherapy's efficacy with primary and secondary endpoints focusing on response rates, survival, and biomarker analysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.36%
Tags
-
Rhea-AI Summary
Puma Biotechnology, Inc. (PBYI) CEO Alan H. Auerbach to present at B. Riley Securities 4th Annual Oncology Conference on January 18, 2024. Replay available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.55%
Tags
conferences
-
Rhea-AI Summary
Puma Biotechnology, Inc. (PBYI) announced the design of the Phase II trial of alisertib for the treatment of patients with HER2-negative, hormone receptor-positive metastatic breast cancer. The trial will evaluate alisertib in combination with endocrine treatment and is expected to initiate in the second half of 2024. The primary efficacy endpoints will include objective response rate, duration of response, disease control rate, and progression-free survival. The Company plans to engage with global regulatory agencies for the design of a pivotal Phase III trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.99%
Tags
Rhea-AI Summary
Puma Biotechnology announced the grant of an inducement restricted stock unit award to a new non-executive employee. The award covers 15,000 shares of Puma common stock and vests over a three-year period. It was granted under Puma's 2017 Employment Inducement Incentive Award Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.2%
Tags
none
-
Rhea-AI Summary
Puma Biotechnology, Inc. (NASDAQ: PBYI) reported financial results for Q3 2023, with product revenue of $51.6 million, a decrease from $54.3 million in Q3 2022. Net income for Q3 2023 was $5.8 million, compared to a net loss of $0.4 million in Q3 2022. The company had cash, cash equivalents, and marketable securities of $85.0 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.65%
Tags
-
Rhea-AI Summary
Puma Biotechnology to host conference call following release of Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
conferences earnings
Rhea-AI Summary
Puma Biotechnology presents Phase I/II trial results of alisertib plus pembrolizumab for treatment of Rb-deficient head and neck squamous cell carcinoma at AACR-NCI-EORTC Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the current stock price of PUMA BIOTECHNOLOGY (PBYI)?

The current stock price of PUMA BIOTECHNOLOGY (PBYI) is $2.75 as of December 20, 2024.

What is the market cap of PUMA BIOTECHNOLOGY (PBYI)?

The market cap of PUMA BIOTECHNOLOGY (PBYI) is approximately 139.8M.

What does Puma Biotechnology Inc (PBYI) specialize in?

Puma Biotechnology specializes in developing and commercializing innovative cancer treatments, focusing on in-licensing drug candidates that have undergone initial clinical testing.

What is NERLYNX?

NERLYNX is an oral version of neratinib developed by Puma Biotechnology for the treatment of HER2-positive breast cancer.

What is alisertib?

Alisertib is a selective inhibitor of aurora kinase A, designed to disrupt mitosis and induce apoptosis in rapidly proliferating tumor cells.

What is Puma Biotechnology's approach to drug development?

Puma focuses on in-licensing innovative drug candidates, advancing their development through clinical testing, and eventually commercializing them for cancer treatment.

How does NERLYNX work?

NERLYNX inhibits the HER2 receptor, which is involved in the growth and spread of HER2-positive breast cancer cells.

What types of cancer is alisertib aimed at treating?

Alisertib is targeted at various forms of cancer due to its mechanism of disrupting mitosis in tumor cells.

Does Puma Biotechnology collaborate with other companies?

Yes, Puma Biotechnology engages in partnerships and collaborations to advance the development and commercialization of its drug candidates.

What are some recent achievements of Puma Biotechnology?

Recent achievements include the successful commercialization of NERLYNX and ongoing development of alisertib.

What is the company's financial condition?

Puma Biotechnology has a robust financial foundation, supporting its research and development initiatives and commercialization strategies.

Why is Puma Biotechnology significant in the biopharmaceutical industry?

Puma Biotechnology is significant due to its innovative cancer therapies, strategic development pipeline, and commitment to improving patient outcomes.

PUMA BIOTECHNOLOGY INC

Nasdaq:PBYI

PBYI Rankings

PBYI Stock Data

139.80M
38.59M
15.14%
67.8%
6.08%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
LOS ANGELES